Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Company Overview Linnaeus Therapeutics is a biotechnology company engaged in the identification and development of topically deliverable small molecule agents that modulate skin pigmentation. Problem Many dermatologic conditions result in skin that appears darker or lighter than normal, including acne, psoriasis, vitiligo, and injuries from solar, thermal, and mechanical trauma. Patients perceive these changes as disfiguring, which results in significant anxiety, frustration, and depression. There is a large unmet need for safe and effective approaches to modulate skin pigmentation, as individuals across the globe turn to unsuccessful and unsafe methods in attempts to normalize skin color, or alter skin tone for perceived aesthetic benefit. The estimated global market for skin darkening and lightening agents is estimated at over $20 billion annually, with $5 billion spent in the U.S. on skin “tanning” alone. Many of these currently utilized approaches rely on either 1) UV tanning beds, which cause DNA damage and contribute to premature aging, wrinkles, and skin cancer; 2) synthetic chemicals that react with skin to create an artificial, superficial cosmetic change in skin tone without actually influencing skin pigment production; or 3) potentially harmful agents or procedures that are expensive, not especially effective, and can cause additional tissue damage, scarring, or cancer. Solution The founders of Linnaeus Therapeutics have developed a platform approach to modulate skin pigmentation by either increasing or decreasing melanin pigment production by skin cells using small molecule compounds suitable for topical delivery. In vitro studies have demonstrated the ability of several compounds to modulate effectively the melanin content of engineered human skin tissues. One of the studied compounds also induces pigmentation, or “tans,” normal mouse skin when applied as a topical cream in an in vivo study. Importantly, pigmentation modulation in this model is achieved without the DNA damaging effects of UV radiation exposure. Future pipeline indications may explore the potential to decrease the rate of skin cancer through the regular application of pigment modulating agents to high-risk populations. Founder Information Todd Ridky M.D., Ph.D., Co-Founder, is an active physician-scientist, practicing dermatologist, and expert in human skin biology. Dr. Ridky is an Assistant Professor in the Department of Dermatology at the University of Pennsylvania. He received a B.S. in chemistry from the University of North Carolina at Chapel Hill, a Ph.D. in Biochemistry and M.D. from Case Western Reserve University, and completed dermatology residency and epithelial biology postdoctoral fellowship at Stanford University. Contact: Dora Mitchell Asst. Dir., PCI Ventures University of Pennsylvania [email protected] 215.573.4504 Chris Natale, Co-Founder, received a B.S in Biochemistry and Molecular Biology from Penn State University, and is currently a Ph.D. candidate in the Cell and Molecular Biology graduate program and part of the Developmental, Stem Cell, and Regenerative Biology graduate group at the University of Pennsylvania. Basic science discoveries during his thesis research in Dr. Ridky’s laboratory inspired the formation of Linnaeus Therapeutics.